SPECIAL FEATURES

CCR Translations

1821
The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime?
Michael A. Postow, Margaret K. Callahan, and Jedd D. Wolchok
See article p. 2039

1824
Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
Augusto Villanueva and Josep M. Llovet
See article p. 2090

1827
In Search of a Real "Targeted" Therapy for Thyroid Cancer
Marcia S. Brose
See article p. 2056

CCR New Strategies

1830
New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy
Mei Dong, Alexandria T. Phan, and James C. Yao

1837
Statistical Issues and Recommendations for Noninferiority Trials in Oncology: A Systematic Review
Shiro Tanaka, Yousuke Kinjo, Yoshiaki Kataoka, Kenichi Yoshimura, and Satoshi Teramukai

Statistics in Clinical Cancer Research

Statistics in Clinical Cancer Research

1848
Abiraterone in Prostate Cancer: A New Angle to an Old Problem
Mark N. Stein, Susan Goodin, and Robert S. DiPaola

1855
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
A. Nigel Brooks, Elaine Kilgour, and Paul D. Smith

Molecular Pathways

Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance
Kevin G. Chen and Branimir I. Sikic

HUMAN CANCER BIOLOGY

Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors
Carlo Visco, Francesco Maura, Giacomo Tuana, Luca Agnelli, Marta Lionetti, Sonia Fabris, Elisabetta Novella, Ilaria Giaretti, Gianluigi Reda, Wilma Barcellini, Luca Baldini, Antonino Neri, Francesco Rodeghiero, and Agostino Corteletti

MAPKAP Kinase 2 Overexpression Influences Prognosis in Gastrointestinal Stromal Tumors and Associates with Copy Number Variations on Chromosome 1 and Expression of p38 MAP Kinase and ETV1
Peter Birner, Andrea Beer, Ursula Vinatzer, Susanne Stary, Romana Höflberger, Nadine Nirtl, Fritz Wrb, Berthold Streubel, and Sebastian F. Schoppmann

Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress–Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response
Sabrina Manni, Alessandra Brancalion, Laura Quotti Tubi, Anna Colpo, Laura Pavan, Anna Cabreda, Elisa Ave, Fortunato Zaffino, Giovanni Di Maira, Maria Ruzzene, Fausto Adami, Renato Zambello, Maria Rita Pitari, Pierfrancesco Tassone, Lorenzo A. Pinna, Carmela Guerrieri, Gianpiero Semenzato, and Francesco Piazza

Glioblastoma Stem–like Cell Lines with Either Maintenance or Loss of High-Level EGFR Amplification, Generated via Modulation of Ligand Concentration
Alexander Schulte, Hauke S. Günther, Tobias Martens, Svenja Zapf, Sabine Riedel, Clemens Wülfing, Malgorzata Stoupiec, Manfred Westphal, and Katrin Lamszus
1914 L1 Cell Adhesion Molecule Promotes Tumorigenicity and Metastatic Potential in Non–Small Cell Lung Cancer
Josephine Hai, Chang-Qi Zhu, Bizhan Bandarchi, Yu-Hui Wang, Roya Navab, Frances A. Shepherd, Igor Jurisica, and Ming-Sound Tsao

1925 Immune Suppression in Premalignant Respiratory Papillomas: Enriched Functional CD4+ Foxp3+ Regulatory T Cells and PD-1/PD-L1/L2 Expression
Lynda J. Hatam, James A. DeVoti, David W. Rosenthal, Fung Lam, Allan L. Abramson, Bettie M. Steinberg, and Vincent R. Bonagura

1936 Integrative Genomics Identified RFC3 As an Amplified Candidate Oncogene in Esophageal Adenocarcinoma

1947 Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis
Yang Zhang, Yihua Sun, Yunjian Pan, Chenguang Li, Lei Shen, Yuan Li, Xiaoyang Luo, Ting Ye, Rui Wang, Haichuan Hu, Hang Li, Lei Wang, William Pao, and Haiquan Chen

IMAGING, DIAGNOSIS, PROGNOSIS

1979 ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress
Colby M. Chapman, Xiaameng Sun, Mark Roschewski, Georg Aue, Mohamed Faroouqui, Lawrence Stennett, Federica Gibellini, Diane Arthur, Patricia Pérez-Galán, and Adrian Wiestner

1992 Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression to Invasive Breast Cancer
Alain Mange, Jérôme Lacombe, Caroline Bacoul-Mollevi, Marta Jarlier, Pierre-Jean Lamy, Philippe Rouanet, Thierry Maudelonde, and Jérôme Solassol

2001 Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children’s Cancer Leukaemia Group (CCLG), Société Française d’Oncologie Pédiatrique (SFOP), and International Society for Pediatric Oncology (SIOP)

2024 18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy

CANCER THERAPY: PRECLINICAL

1954 Impaired Cognitive Function and Hippocampal Neurogenesis following Cancer Chemotherapy
Lori-Ann Christie, Munjul M. Acharya, Vipan K. Parihar, Anna Nguyen, Vahan Martirosian, and Charles L. Limoli

1966 Cyclin-Dependent Kinase 7/9 Inhibitor SNS-032 Abrogates FIP1-like-1 Platelet-Derived Growth Factor Receptor α and Bcr-Abl Oncogene Addiction in Malignant Hematologic Cells
Yongbin Wu, Chun Chen, Xiaoyang Sun, Xianping Shi, Bei Jin, Ke Ding, Sai-Ching Jim Yeung, and Jingxuan Pan

2012 A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma
Idoia Garcia, Gemma Mayol, José Rios, Gema Domenech, Nai-Kong V. Cheung, André Oberthuer, Matthias Fischer, John M. Maris, Garrett M. Brodeur, Barbara Hero, Eva Rodríguez, Mariona Suñol, Patricia Galvan, Carmen de Torres, Jaume Mora, and Cinzia Lavarino

2024 18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy
A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration

Xavier M. Keutgen, Filippo Filicori, Michael J. Crowley, Yongchun Wang, Theresa Scognamiglio, Rana Hoda, Daniel Buitrago, David Cooper, Martha A. Zeiger, Rasa Zarnegar, Olivier Elemento, and Thomas J. Fahey III

CANCER THERAPY: CLINICAL

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Peter A. Prieto, James C. Yang, Richard M. Sherry, Marybeth S. Hughes, Udai S. Kammula, Donald E. White, Catherine L. Levy, Steven A. Rosenberg, and Giao Q. Phan
See commentary p. 1821

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer
Wen Wee Ma, Wells A. Messersmith, Grace K. Dy, Colin D. Weekes, Amy Whitworth, Chen Ren, Manoj Maniar, Francois Wilhelm, S. Gail Eckhardt, Alex A. Adjei, and Antonio Jimeno

Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
See commentary p. 1827

Implications of Plasma Protein Binding for Pharmacokinetics and Pharmacodynamics of the γ-Secretase Inhibitor RO4929097
Jianmei Wu, Patricia M. Lo Russo, Larry H. Matherly, and Jing Li

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
Eleni M. Karapanagiotou, Victoria Roulstone, Katie Twigger, Merced Ball, Mary Anne Tanay, Chris Nutting, Kate Newbold, Martin E. Gore, James Larkin, Konstantinos N. Syrigos, Matt Coffey, Brad Thompson, Karl Mettinger, Richard G. Vile, Hardev S. Pandha, Geoff D. Hall, Alan A. Melcher, John Chester, and Kevin J. Harrington

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
Cody J. Peer, Tristan M. Sissung, AeRang Kim, Lokesh Jain, Sukyung Woo, Erin R. Gardner, C. Tyler Kirkland, Sarah M. Troutman, Bevin C. English, Emily D. Richardson, Joel Federspiel, David Venzon, William D. Figg

Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer
Michael Milosevic, Padraig Warde, Cynthia Ménard, Peter Chung, Ants Toi, Adrian Ishkanian, Michael McLean, Melanie Pintilie, Jenna Sykes, Mary Gospodarowicz, Charles Catton, Richard P. Hill, and Robert Bristow

Correction: Molecular Imaging of TGFβ-Induced Smad2/3 Phosphorylation Reveals a Role for Receptor Tyrosine Kinases in Modulating TGFβ Signaling
Correction: Valproic Acid Prolongs Survival Time of Severe Combined Immunodeficient Mice Bearing Intracerebellar Orthotopic Medulloblastoma Xenografts

Correction: Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

ABOUT THE COVER

High-level EGFR gene amplification can be retained in glioblastoma stem-like cell lines established and propagated without recombinant EGF. In contrast, high-level amplification is lost in parallel cell lines from the same tumors established with EGF supplementation. Cell lines with high-level EGFR amplification produce highly aggressive xenograft tumors in the brains of nude mice, retaining the EGFR amplification as shown in the cover figure, whereas counterpart cell lines, lacking high-level amplification, are either nontumorigenic or grow significantly more slowly in vivo. For details, see the article by Schulte and colleagues on page 1901 of this issue.